NL8502017A - Nieuw, in het bloed geidentificeerd eiwit, werkwijze ter bereiding daarvan, werkwijze ter bepaling van dit eiwit en tevens van t-pa-remmer, en farmaceutische preparaten die het eiwit bevatten. - Google Patents

Nieuw, in het bloed geidentificeerd eiwit, werkwijze ter bereiding daarvan, werkwijze ter bepaling van dit eiwit en tevens van t-pa-remmer, en farmaceutische preparaten die het eiwit bevatten. Download PDF

Info

Publication number
NL8502017A
NL8502017A NL8502017A NL8502017A NL8502017A NL 8502017 A NL8502017 A NL 8502017A NL 8502017 A NL8502017 A NL 8502017A NL 8502017 A NL8502017 A NL 8502017A NL 8502017 A NL8502017 A NL 8502017A
Authority
NL
Netherlands
Prior art keywords
inhibitor
protein
plasma
urokinase
methods
Prior art date
Application number
NL8502017A
Other languages
English (en)
Dutch (nl)
Original Assignee
Tno
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tno filed Critical Tno
Priority to NL8502017A priority Critical patent/NL8502017A/nl
Priority to DE8686201213T priority patent/DE3674955D1/de
Priority to AT86201213T priority patent/ATE57471T1/de
Priority to EP86201213A priority patent/EP0208383B1/en
Priority to US06/884,418 priority patent/US5004802A/en
Priority to JP61164544A priority patent/JP2512437B2/ja
Publication of NL8502017A publication Critical patent/NL8502017A/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8132—Plasminogen activator inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NL8502017A 1985-07-12 1985-07-12 Nieuw, in het bloed geidentificeerd eiwit, werkwijze ter bereiding daarvan, werkwijze ter bepaling van dit eiwit en tevens van t-pa-remmer, en farmaceutische preparaten die het eiwit bevatten. NL8502017A (nl)

Priority Applications (6)

Application Number Priority Date Filing Date Title
NL8502017A NL8502017A (nl) 1985-07-12 1985-07-12 Nieuw, in het bloed geidentificeerd eiwit, werkwijze ter bereiding daarvan, werkwijze ter bepaling van dit eiwit en tevens van t-pa-remmer, en farmaceutische preparaten die het eiwit bevatten.
DE8686201213T DE3674955D1 (de) 1985-07-12 1986-07-10 Im blut identifiziertes protein, ein verfahren zu seiner zubereitung, ein verfahren fuer die bestimmung dieses proteins und ebenfalls des t-pa-hemmungsfaktors und pharmazeutische zusammensetzungen, die dieses protein enthalten.
AT86201213T ATE57471T1 (de) 1985-07-12 1986-07-10 Im blut identifiziertes protein, ein verfahren zu seiner zubereitung, ein verfahren fuer die bestimmung dieses proteins und ebenfalls des t-pa-hemmungsfaktors und pharmazeutische zusammensetzungen, die dieses protein enthalten.
EP86201213A EP0208383B1 (en) 1985-07-12 1986-07-10 Novel protein which has been identified in blood, a process for preparing the same, a process for assaying this protein and also t-pa inhibitor, and pharmaceutical compositions containing said protein
US06/884,418 US5004802A (en) 1985-07-12 1986-07-11 100KDa protein from blood which binds to and inhibits the activity of plasminogen activators
JP61164544A JP2512437B2 (ja) 1985-07-12 1986-07-12 血液蛋白質、その調製方法、前記蛋白質およびｔ−ＰＡ阻害剤をアツセイする方法、および前記蛋白質を含有する製薬学的組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL8502017A NL8502017A (nl) 1985-07-12 1985-07-12 Nieuw, in het bloed geidentificeerd eiwit, werkwijze ter bereiding daarvan, werkwijze ter bepaling van dit eiwit en tevens van t-pa-remmer, en farmaceutische preparaten die het eiwit bevatten.
NL8502017 1985-07-12

Publications (1)

Publication Number Publication Date
NL8502017A true NL8502017A (nl) 1987-02-02

Family

ID=19846293

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8502017A NL8502017A (nl) 1985-07-12 1985-07-12 Nieuw, in het bloed geidentificeerd eiwit, werkwijze ter bereiding daarvan, werkwijze ter bepaling van dit eiwit en tevens van t-pa-remmer, en farmaceutische preparaten die het eiwit bevatten.

Country Status (6)

Country Link
US (1) US5004802A (ja)
EP (1) EP0208383B1 (ja)
JP (1) JP2512437B2 (ja)
AT (1) ATE57471T1 (ja)
DE (1) DE3674955D1 (ja)
NL (1) NL8502017A (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5372719A (en) * 1992-03-30 1994-12-13 Perseptive Biosystems, Inc. Molecular imaging
US5474766A (en) * 1992-12-18 1995-12-12 Washington University Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator
US5607841A (en) * 1994-06-20 1997-03-04 Lipinski; Boguslaw Preparation and proteolytic degradation of a macromolecular protein complex from fibrinogen
CN105517565A (zh) 2013-01-22 2016-04-20 田纳西大学研究基金会 组织纤溶酶原激活物抗体及其用途

Also Published As

Publication number Publication date
US5004802A (en) 1991-04-02
JPS6277326A (ja) 1987-04-09
ATE57471T1 (de) 1990-11-15
DE3674955D1 (de) 1990-11-22
EP0208383A1 (en) 1987-01-14
JP2512437B2 (ja) 1996-07-03
EP0208383B1 (en) 1990-10-17

Similar Documents

Publication Publication Date Title
Aoki et al. The behavior of alpha2-plasmin inhibitor in fibrinolytic states.
Hackeng et al. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa.
Lijnen et al. Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma.
Colucci et al. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation.
Levin Quantitation and properties of the active and latent plasminogen activator inhibitors in cultures of human endothelial cells
Debrock et al. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms
Robbie et al. The roles of α2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis
Mutch et al. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI
Larrieu et al. Comparative effects of fibrinogen degradation fragments D and E on coagulation
JP2008289498A (ja) 精製されたマルチメラ−ゼ
Collen et al. In vivo studies of a synthetic inhibitor of thrombin
Edelberg et al. The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. The effects of fibrinogen, heparin, vitronectin, and lipoprotein (a).
Patston et al. Reactivity of alpha 1-antitrypsin mutants against proteolytic enzymes of the kallikrein-kinin, complement, and fibrinolytic systems.
Kowalski et al. Circulating fibrinogen degradation products (FDP) in dog blood after intravenous thrombin infusion
Lijnen et al. Interaction of heparin with histidine-rich glycoprotein and with antithrombin III
Loskutoff et al. Fibrinolytic system of cultured endothelial cells: regulation by plasminogen activator inhibitor
Marlar et al. Contribution of plasma proteinase inhibitors to the regulation of activated protein C in plasma
Mattsson et al. Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro
Henderson et al. The Mechanism of Enhanced Streptokinase‐Induced Clot Lysis following In‐vitro Factor‐XIII Inactivation
NL8502017A (nl) Nieuw, in het bloed geidentificeerd eiwit, werkwijze ter bereiding daarvan, werkwijze ter bepaling van dit eiwit en tevens van t-pa-remmer, en farmaceutische preparaten die het eiwit bevatten.
Alkjaersig et al. Formation of soluble fibrin oligomers in purified systems and in plasma
Abildgaard Inhibition of the thrombin-fibrinogen reaction by α2-macroglobulin, studied by N-terminal analysis
Edelberg et al. Lipoprotein (a) promotes plasmin inhibition by α2-antiplasmin
Develter et al. Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabody
Gurewich et al. Spontaneous clot lysis in whole human plasma by endogenous tissue type and urokinase type plasminogen activators: demonstration of a promoting effect by t-PA and by platelets on urokinase

Legal Events

Date Code Title Description
A1B A search report has been drawn up
BV The patent application has lapsed